Ac2-26
An Annexin A1 (AnxA1)-derived N-terminal peptide used in inflammation-resolution research, with recent preclinical work in osteoarthritis models.
Tag
Pages related to Osteoarthritis.
An Annexin A1 (AnxA1)-derived N-terminal peptide used in inflammation-resolution research, with recent preclinical work in osteoarthritis models.
In osteoarthritic human chondrocytes, a BMP7-derived peptide (p[63–82]) shifted gene expression toward collagen assembly pathways and increased glycosaminoglycan content. A repair-flavored signal in human cells, not a joint therapy yet.
A 2026 mouse study reports that Ac2‑26, an Annexin A1–derived pro‑resolving peptide, reduced pain-like sensitivity and several joint damage readouts in collagenase-induced osteoarthritis. It’s preclinical—but it illustrates the logic of “resolution pharmacology.”